WTA Announces SRY Gene Test Requirement for Player Eligibility, According to Reports

1-Minute Brief

The reported genetic testing policy signals a change in eligibility standards for women's professional tennis, according to multiple sources.

Key Facts

• Players will need to take a test for the SRY gene, which helps determine biological sex, according to the WTA as reported by Al Jazeera and BBC News.
• Fox News reports that the WTA's previous policy allowed transgender-identifying males to compete under testosterone limits, but this has been replaced by genetic testing.
• The SRY gene test is described as a one-time requirement for eligibility to compete on the WTA Tour, according to Al Jazeera and Fox News.
• BBC News reports that the Women's Tennis Association will ask all players to undergo genetic sex testing.
• Al Jazeera states the WTA said the SRY gene is used in determining biological sex.

What Happened

Multiple news outlets report that the Women's Tennis Association (WTA) has announced a requirement for players to undergo a one-time SRY gene test to determine eligibility for participation on the WTA Tour, replacing its previous testosterone-based policy.

Why It Matters

If implemented, this policy change may affect eligibility for some athletes and reflects ongoing debates about fairness and inclusion in women's sports. The adoption of genetic testing would represent a significant shift in how governing bodies address gender and competition. There is no confirmation from major outlets or official WTA statements beyond the cited sources. The implementation and scope of the reported policy remain unverified.

What's Next

According to reports, players would need to comply with the new genetic testing requirement to participate in WTA events. Reactions from athletes, advocacy groups, and sports organizations may follow if the policy is enacted.